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Background: Statins (HMG-CoA reductase inhibitors) represent a major class of compounds for the treatment of
hypercholesterolemia due to their ability to inhibit de novo cholesterol synthesis. In addition to their
hypolipidemic effects, chemoprotective properties have been attributed to statins as well. These effects involve
multiple mechanisms, which, however, are not known in detail. The aim of our study was to assess in
non-malignant as well as cancer cells the impact of simvastatin on the amount of cytosolic lipid droplets (LDs)
implicated in many biological processes including proliferation, inflammation, carcinogenesis, apoptosis,
necrosis or growth arrest.
Methods: Human embryonic kidney cells HEK-293T and human pancreatic cancer cells MiaPaCa-2 were treated
with simvastatin (6 and 12 μM) for 24 and 48 hours respectively. Neutral lipid probe Nile Red was used for
detection of LDs by fluorescence microscopy. Cellular cholesterol content was determined by HPLC. Changes in
expression of genes related to lipid metabolism in simvastatin-treated MiaPaCa-2 cells were examined by DNA
microarray analysis. Validation of gene expression changes was performed using quantitative RT-PCR.
Results: The treatment of the cells with simvastatin increased their intracellular content of LDs in both
non-malignant as well as cancer cells, partially due to the uptake of cholesterol and triacylglyceroles from
medium; but in particular, due to enhanced synthesis of triacylglyceroles as proved by significant overexpression
of genes related to de novo synthesis of triacylglyceroles and phospholipids. In addition, simvastatin also
markedly influenced expression of genes directly affecting cell proliferation and signaling.
Conclusions: Simvastatin treatment led to accumulation of cytosolic LDs within the examined cells, a
phenomenon which might contribute to the antiproliferative effects of statins.
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reproduction in any medium, provided the orThe first statin was discovered in 1976, and since 1980
they have been introduced into clinical practice [1].
In addition to their hypolipidemic effects, statins
exert also numerous additional biological activities me-
diated by various products of the mevalonate pathway,
such as anti-inflammatory and immunomodulatory ac-
tivities, effects on endothelial function, anti-oxidative
effects, or effects on cell proliferation and apoptosis,
etc. [2,3].
Chemoprotective effects of statins have been attrib-
uted to their impact on protein prenylation. Among
prenylated proteins, the low molecular weight GTP-al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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merous cellular functions including cell proliferation. In
normal, untransformed cells, the Ras proteins cycle be-
tween an inactive GDP-bound state and active GTP-
bound state at the plasma membrane (PM) [4]. Unlike
activation mechanisms under physiological conditions,
activating mutations of ras genes (mostly in K-ras gene)
occur frequently in malignant tissues.
These mutations result in a loss of GTPase activity,
which leads to permanent K-Ras protein activation and
continuous initiation of downstream signal cascades re-
lated to cell proliferation. This results in deregulated
growth of cell populations and development of cancer.
It was found that approximately 30% of all human can-
cers harbor activating mutations of ras genes. In pan-
creatic cancer, these mutations of the K-ras oncogene
are present in up to 90% of cases [5,6]. Statin-mediated
inhibition of Ras protein farnesylation thus seems to be
a promising adjuvant approach for the treatment of
pancreatic cancer and cancer in general, and this is why
the possible anticancer potential of statins is being in-
tensively studied [7-9].
The molecular mechanisms of the anticancer effects
of statins are complex and depend on many factors af-
fecting their pharmacokinetics and pharmacodynamics
[9,10]. Apart from common cellular processes affected
by statins, their impact on metabolism of cytosolic
lipid droplets (LDs) has not been studied in detail.
Cytosolic LDs, previously considered to be passive fat
deposits within the cells, are being currently regarded
as dynamic, regulated organelles with multiple bio-
logical functions [11]. The mechanisms of LDs biogen-
esis and turnover are not currently understood and
several hypotheses have been suggested [12,13]. LDs
exist virtually in any kind of cell, ranging from bacteria
to yeasts, plants, and higher mammals. In mammalian
cells and in most cultured cell lines, LDs consist of a
core of neutral lipids, predominantly triacylglyceroles
(TG) or cholesteryl esters (CE), that are surrounded by
a monolayer of phospholipids, free cholesterol and as-
sociated proteins. The neutral lipids that are stored in
LDs are used for metabolism, membrane synthesis
(phospholipids and cholesterol) and steroid synthesis
[14]. In addition, LDs have a crucial role as a deposit of
cholesterol in the form of cholesteryl esters, as part of
complex homeostatic mechanisms that are involved in
regulation of the intracellular free cholesterol levels
[14]. Di Vito and co-workers reported a highly dynamic
role of intracellular LDs in many important develop-
mental processes including proliferation, inflammation,
apoptosis, growth arrest and necrosis [15,16]. Based on
these data, the effect of statins on pancreatic cancer cell
proliferation might be caused by the changes in intra-
cellular LDs amount.The aim of the present study was thus to assess the
effect of simvastatin on intracellular LDs in human
healthy and pancreatic cancer cells, and to relate these
effects to antiproliferative activities of statins.
Results
Analysis of intracellular LDs content
a) HEK 293T cells
Occasional presence of LDs was observed in HEK 293T
cells cultured in the medium supplement with FBS
(Figure 1a), which increased markedly in the cells ex-
posed to simvastatin (12 μM) (Figure 1b). To eliminate
the effect of possible cholesterol uptake from the
medium, the cells were cultured in the FBS free me-
dium. The absence of FBS resulted in disappearance of
LDs from the cells not exposed to simvastatin (Figure 1c).
However, compared to simvastatin-untreated cells
(Figure 1c), the LDs content in the cells cultured in
presence of 12 μM simvastatin in FBS free medium in-
creased again (Figure 1d) and was comparable to the
control cells (Figure 1a).b) MiaPaCa-2 cells
Content of the LDs in the MiaPaCa-2 cells was in general
higher as compared to that in HEK-293T cells (Figure 2a
vs. Figure 1a). Due to very high LDs concentration in
MiaPaCa-2 cells there were not detectable changes in LDs
amounts after 24 hours of treatment. Therefore, the
MiaPaCa-2 cells were cultured in the FBS free medium
supplemented with 12 μM simvastatin for 48 hours. Even
after this prolonged exposure to simvastatin, the changes in
the LDs amount in MiaPaCa-2 cells (Figure 2b) were not as
evident as in HEK cells. Similarly, the amount of LDs was
decreased in the MiaPaCa-2 cells cultured in the FBS free
medium compared to those containing FBS (Figure 2c vs.
Figure 2a). The LDs content in the MiaPaCa-2 cells treated
with simvastatin in the FBS free medium was again slightly
higher to that in the cells cultured in the same medium in
absence of simvastatin (Figure 2d vs. Figure 2c) and sub-
stantially lower compared to that in the control cells (in the
FBS supplemented medium) (Figure 2a).Analysis of intracellular cholesterol content
To study the composition of accumulated LDs, MiaPaCa-
2 cells were exposed to 12 μM simvastatin for 48 hours.
The cells were then harvested and cellular cholesterol
content was quantified and compared to that in the cells
cultured in the absence of simvastatin. Only free choles-
terol was detected in the analyzed samples, but no signifi-
cant differences between cholesterol content in the
control cells and those treated with simvastatin were de-
tectable (Table 1).
Figure 1 Intracellular lipid droplets in HEK-293T cells staining by Nile Red (10 ng/ml), a) control cells, b) simvastatin treated cells, c)
cells cultivated in FBS free medium, d) cells treated with simvastatin in FBS free medium. Simvastatin used in concentration 12 μM, 24 hrs
exposure. FBS, fetal bovine serum. Scale bar represents 10 μm. Arrows indicate lipid droplets.
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a) The effect of simvastatin on expression of genes related
to lipid metabolism
Gene expression microarray analysis revealed that
6 μM concentration of simvastatin was sufficient for
up-regulation of three genes related to the enzymes of
the mevalonate pathway; this effect was pronounced by
higher concentration of simvastatin (12 μM) (Table 2).
The most upregulated gene of mevalonate pathway was
HMGCS1 (Table 2) coding for an enzyme catalyzing con-
densation of acetyl-CoA with acetoacetyl-CoA to form
HMG-CoA. The other up-regulated gene, HMGCR (3-hy-
droxy-3-methylglutaryl-coenzyme A Reductase) is respon-
sible for conversion of the HMG-CoA to mevalonic acid
and it is target of statins. The MVD (mevalonate pyro-
phosphate decarboxylase), whose gene transcription was
doubled upon treatment with simvastatin, catalyzes con-
version of mevalonate pyrophosphate into isopentenyl
pyrophosphate [17].
Treatment of simvastatin also lead to significant up-
regulation of two genes coding for enzymes catalyzing
de novo synthesis of phospholipids and glycerolipids, in
particular 1-acyl-sn-glycerol-3-phosphate acyltransferase
beta (AGPAT2) and lipid phosphate phosphohydrolase 1
(PPAP2A) (Table 2). AGPAT2 converts lysophosphatidicacid to phosphatidic acid, the second step in de novo
phospholipid biosynthesis [18]. PPAP2A is a member of
the phosphatidic acid phosphatase (PAP) family. PAPs
convert phosphatidic acid to diacylglycerol, and func-
tion in de novo synthesis of glycerolipids as well as in
receptor-activated signal transduction mediated by
phospholipase D. This protein plays an active role in hy-
drolysis and uptake of lipids from extracellular space
and represents a key enzyme in the regulation of lipid
synthesis in general [19].
In addition, ACSS2 coding for acyl-CoA synthetase
short-chain family member 2 (the member of Acyl-CoA
synthases (thiokinases)) was also significantly upregulated
by simvastatin (Table 2). It catalyzes activation of long
chain fatty acids and esterifies them to coenzyme A, be-
fore they undergo oxidative degradation to be utilized for
synthesis of complex lipids (e.g., TG or membrane lipids),
or be attached to proteins as lipid anchors [20].
The last significantly up-regulated gene related to
cholesterol and lipid homeostasis was ABCA7 gene
(Table 2). The protein encoded by this gene is a mem-
ber of the superfamily of ATP-binding cassette (ABC)
transporters, that transport a wide variety of substrates
across extra- and intracellular membranes, including
metabolic products, lipids and sterols, and drugs [21].
Figure 2 Intracellular lipid droplets in MiaPaCa-2 cells staining by Nile Red (10 ng/ml), a) control cells, b) simvastatin treated cells, c)
cells cultivated in FBS free medium, d) cells treated with simvastatin in FBS free medium. Simvastatin used in concentration 12 μM, 48 hrs
exposure. FBS, fetal bovine serum. Scale bar represents 10 μm.
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in cell proliferation
Besides genes involved in lipid metabolism, and consistent
with reported antiproliferative effects of statins, simva-
statin treatment affected expression of a large number of
genes implicated in cell cycle regulation, DNA replication
or cell signaling, including MAP kinase signaling pathway.
Simultaneously, the genes involved in apoptosis and au-
tophagy have been found to be differentially expressed
(see Table 3, for detailed list of genes, see ArrayExpress
database, accession number E-MTAB-1501).
Validation of gene expression changes was performed
using quantitative RT-PCR (see results in Additional file 1).
Discussion
Present study demonstrates that the exposure of human
embryonic kidney cells HEK-293T as well as pancreaticTable 1 Cholesterol content in MiaPaCa-2 exposed to simvast
Control Simva
Total cholesterol [nmol] 97 ± 7
Free cholesterol [nmol] 98 ± 8
P-value NS
Cells were exposed to simvastatin (12 μM) for 48 hrs. Data represent the mean of trcancer cells MiaPaCa-2 to simvastatin, a competitive in-
hibitor of HMG-CoA reductase, results in increased ac-
cumulation of intracellular LDs. As LDs play role in
many important developmental processes including pro-
liferation, apoptosis, growth arrest and necrosis, our data
seems to be in line with the effect of statins on lipid me-
tabolism and cancer development [14].
It was previously described that LDs contain predomin-
antly TG and CE [14]. Based on this data, a decrease of
intracellular LDs after inhibition of mevalonate pathway
by simvastatin was expected. However, the intracellular
amount of LDs in both noncancerous HEK 293T as well
as malignant pancreatic cancer MiaPaCa-2 cells increased
after the exposure to simvastatin.
To account for this phenomenon, we quantified the
cholesterol content in studied cells. Surprisingly, the intra-
cellular cholesterol did not differ between statin-exposedatin
statin-treated % Control P-value
91 ± 6 94% NS
93 ± 7 95% NS
NS - -
iplicate determinations ± SD; NS, not significant.
Table 2 The effect of simvastatin on expression of genes involved in lipid metabolism in MiaPaCa-2 cells
Gene symbol Product name and related functional pathway RefSeq ID
Fold change after simvastatin
FDR
6 μM 12 μM
HMGCS1 3-hydroxy-3-methylglutaryl-coenzyme A synthase (EC 2.3.3.10) NM_002130.6 3.48 3.63 3.3 × 10-8
Mevalonate pathway (cholesterol synthesis)
HMGCR 3-hydroxy-3-methylglutaryl-coenzyme A reductase (EC 1.1.1.34) NM_000859.1 2.58 3.11 2.1 × 10-6
Mevalonate pathway (cholesterol synthesis)
MVD Mevalonate pyrophosphate decarboxylase (EC 4.1.1.33) NM_002461.1 2.31 2.39 3.4 × 10-7
Mevalonate pathway (cholesterol synthesis)
PPAP2A Phosphatidic acid phosphatase 2a (EC 3.1.3.4) NM_003711.2 1.79 2.25 3.3 × 10-5
Kennedy pathway (triacylglycerol synthesis)
AGPAT2 1-acyl-glycerol-phosphate acyltransferase 2 (EC 2.3.1.51) NM_006412.3 1.71 2.01 5.0 × 10-5
Kennedy pathway (phospholipids and glycerolipids synthesis)
ACSS2 Acyl-CoA synthetase short-chain family member 2 (EC 6.2.1.1) NM_018677.2 2.16 2.22 1.7 × 10-6
Activation of long chain fatty acids
ABCA7 ABC transporter sub-family A member 7 NM_019112.3 1.67 2.03 2.3 × 10-5
Transporter involved in cholesterol and lipid homeostasis
Simvastatin used in concentration 6 and 12 μM, 24 hrs exposure. Presented are only transcripts with FC > 2.0 or < 0.5 and FDR < 0.05. For full list of differentially
regulated transcripts see the ArrayExpress database, accession number E-MTAB-1501.
Gbelcová et al. Lipids in Health and Disease 2013, 12:126 Page 5 of 9
http://www.lipidworld.com/content/12/1/126compared to untreated cells indicating that accumulation
of other lipids must be responsible for our observation.
In fact, the expression analysis revealed up-regulation of
multiple genes involved in lipid metabolism. The up-
regulated ABCA7 gene coding for transporter involved in
cholesterol and lipid homeostasis is likely to enhance the
cholesterol uptake from medium in the cholesterol-
depleted cells. This is consistent with the observation that
in most cell lines the numbers of LDs are largely deter-
mined by the composition of the culture medium [22].
This correlates with the fact that all nucleated cells tightly
regulate their intracellular free cholesterol concentrations
not only through the endogenous cholesterol synthesis,Table 3 The effect of simvastatin on metabolic pathways
of human pancreatic cancer cells MiaPaCa-2
Path ID Path name FDR
hsa00100 Biosynthesis of steroids 1.1 × 10-12
hsa04110 Cell cycle 1.4 × 10-9
hsa01430 Cell communication 1.1 × 10-6
hsa03030 DNA replication 1.2 × 10-6
hsa04010 MAPK signaling pathway 2.0 × 10-4
hsa00230 Purine metabolism 8.0 × 10-4
hsa03430 Mismatch repair 1.0 × 10-3
hsa00190 Oxidative phosphorylation 1.0 × 10-3
hsa03440 Homologous recombination 1.0 × 10-3
Simvastatin used in concentration 6 and 12 μM, 24 hrs exposure. FDR < 0.001
was used as a cut-off value. Data based on KEGG pathway analysis, FDR- false
discovery rate. For detailed list of genes, see the ArrayExpress database,
accession number E-MTAB-1501.but also through LDL-receptor and ABC transporters-
mediated cholesterol transport [23,24]. Similarly, Iwamoto
et al. concluded that cholesterol depletion induced the up-
regulation of ABCA7 gene expression [25].
However, the amount of intracellular LDs increased also
in the cells treated with simvastatin in FBS free medium
suggesting that de novo lipid synthesis must be responsible
for this phenomenon in the cells cultured in cholesterol-
depleted cultivation medium. Our observations correlate
with the conclusion of Williams et al., who observed an
accumulation of LDs in keratinocytes cultivated in serum
free medium supplemented with lovastatin [26].
As noted before, the second major component of intra-
cellular LDs are TGs. Enhanced TGs synthesis might thus
account for the increase of intracellular LDs in the
simvastatin-treated cells in an effort to balance constant
amount of soluble cytoplasmic fatty compounds while
keeping a constant level of cholesterol.
Indeed, apart from up-regulation of ABCA7 lipid
transporter gene, simvastatin substantially induced also
genes involved in TG and phospholipid de novo biosyn-
thesis (Figure 3); which is in accord with the explan-
ation suggested above for the accumulation of LDs in
the simvastatin-treated cells.
HMG-CoA synthase, which catalyzes condensation of
acetyl-CoA with acetoacetyl-CoA to form HMG-CoA, is
up-regulated (Figure 3). The reduction of HMG-CoA to
mevalonate by HMGCR is inhibited by the simvastatin; in
turn, molecules of HMG-CoA accumulate in the cell
and inhibit HMG-CoA synthase by a feedback product in-
hibition (Figure 3). Consequently, the acetyl-CoA and
acetoacetyl-CoA accumulate in the cells providing a high
Figure 3 Scheme of simvastatin-affected metabolic pathways related to lipid metabolism according to our model. Products of genes
affected by simvastatin are shown bold.
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component of TG (Figure 3).
We have not observed changes in expression of genes en-
coding two key enzymes involved in cytosolic fatty acid bio-
synthesis; namely acetyl-CoA carboxylase (ACC), which
converts acetyl CoA to malonyl CoA and fatty acid syn-
thase (FA synthase) (Figure 3) (data not shown). However
other genes, namely PAP2a and AGPAT2, required for de
novo TG and phospholipids synthesis were upregulated
after cells treatment by higher doses of simvastatin (Table 2).
These two enzymes catalyze reactions downstream to
the rate limiting step of the mentioned routes (Figure 3).
The simvastatin induced increase of TGs and phospho-
lipids synthesis may also explain the aforementioned
up-regulation of ABCA7 gene, because ABCA7 modu-
lates not only cholesterol levels but also phospholipid
release by apolipoproteins in cell cultures [27-29].
Recently, Boren and Brindle observed that induction
of apoptosis resulted in rapid accumulation of cytoplas-
mic LDs and was accompanied by an increase of de novo
neutral lipid synthesis, most likely due to the inhibition
of mitochondrial fatty acid β-oxidation. They showed
that the formation of cytoplasmic LDs was caused by an
apoptosis-induced mitochondrial dysfunction [30], a
phenomenon affected by simvastatin also in our studies.
Simultaneously, simvastatin was able to modulate ex-
pression of a wide array of genes implicated in cell cycleregulation and signaling. It remains to be answered
whether these effects are independent or are functionally
associated with the accumulation of LDs. As LDs are
supposed to be derived from the ER membrane [12,14]
that serves as a pool of many enzymes required for lipid
metabolism as well as the programmed cell death [30,31],
accumulated intracellular LDs in statin-treated cells might
be rather effectors of some pleiotropic effects of statins
than only by-standing phenomenon with no biological
relevance.
In conclusion, simvastatin treatment led to accumula-
tion of cytosolic LDs within both non-cancerous as well
as malignant cells, a phenomenon which might contrib-
ute to their antiproliferative effects.
Methods
Cell cultures and simvastatin treatment
Human embryonic kidney (HEK-293T) and pancreatic
cancer cells (MiaPaCa-2, both cell lines from ATCC,
Manassas, VA, USA) were maintained and grown in a
humidified atmosphere containing 5% CO2 at 37°C in
DMEM supplemented with 10% fetal bovine serum. Cell
viability was assessed by 0.4% trypan blue staining. Sim-
vastatin was added at concentrations equal to its IC50
value for MiaPaCa-2 (12 μM) as reported previously [10]
24 hrs post-inoculation of the cells. For DNA microarray
analyses also 6 μM concentrations of simvastatin were
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(Enzo Life Sciences, NY).Lipid droplets staining
Two neutral lipid dyes, Nile Red (9-diethylamino-
5H-benzo[α]phenoxazine-5-one) and BODIPY® 493/503
(4,4-difluoro-1,3,5,7,8-pentamethyl-4-bora-3α,4α-diaza-s-
indacene) were used for lipid staining. The stock solutions
(1.0 mg/ml) in methanol were stored frozen (−20°C) in
dark. Staining was carried out in fixed cells (4% formalde-
hyde, 20 minutes). The dye was added directly to the fixed
cells to a final concentration of 10 ng/ml and incubated
for 10 minutes. The dye was carefully washed out using
PBS prior to microscopy. LDs were then visualized by
fluorescence microscopy using QuickPHOTO CAMERA
2.1 processing software (Olympus, Tokyo, Japan).Quantification of cellular cholesterol content in MiaPaCa-
2 cells exposed to simvastatin
The cellular cholesterol content in MiaPaCa-2 cells ex-
posed to simvastatin (12 μM) [10] 24 hrs post-inoculation
of MiaPaCa-2 cells were quantified using isotope dilution-
gas chromatography–mass spectrometry (ID-GC-MS).
The amounts of the total (free cholesterol and cholesterol
ester) and free cholesterol were analyzed after additional
48 hrs of incubation (in triplicate) to determine the
amount and form of cholesterol present in the cells ex-
posed to simvastatin. The cell pellet was mixed with D6-
cholesterol (internal standard, 50 mg/l) (Medical Isotopes,
Inc, Pelham, AL, USA), resuspended in ethanol with 9 M
KOH and incubated at 37°C for 3 hrs for complete hy-
drolysis of cholesterol esters. The samples were then di-
luted with water and extracted into hexane. The organic
phase was evaporated at 60°C under a stream of nitrogen.
Dried samples were reconstituted in N,O-bis(trimethylsilyl)
acetamide (TMA) (Merck) and silylated 30 minutes at
room temperature. Relative concentrations of resulting
cholesterol trimethylsilylethers were determined using gas
chromatography (Agilent 6890, Agilent, USA) coupled with
a quadrupole mass detector (Agilent 5973, Agilent, USA).
Analytical conditions were: splitless injection, inlet tem-
perature 300°C, column HP 5MS, temperature gradient
from 200°C to 300°C - 10°C/min, column flow 1 ml/min,
electron impact ionization at 70 mV, single ion monitoring
at 458.4 and 464.4. Absolute intracellular cholesterol levels
were calculated from calibration curves using purified
cholesterol standard (Sigma-Aldrich, USA). The choles-
terol content of simvastatin treated MiaPaCa-2 cells was
normalized to the cell number in the sample.
Cholesterol content is expressed as mean ± SD. The
differences between values acquired were evaluated by
Student’s t-test. Differences were considered statistically
significant when p values were less than 0.05.DNA microarray analysis
The effect of 6 and 12 μM concentrations of simvastatin
on MiaPaCa-2 pancreatic cancer cell gene expression
was investigated 24 h post-inoculation. Cells from two
parallel cultivations (10 cm2 cultivate dish) were lysed in
the stage of subconfluency using the RLT lysis buffer sup-
plied in RNeasy Mini Kit (Qiagen, USA). Total RNA was
isolated by RNeasy Micro Kit (QIAGEN, USA) according
to the procedure for animal cells. Quantity of the RNA
was measured on NanoDrop ND-1000 spectrophotometer
(NanoDrop Technologies LLC, USA). Quality of the RNA
was analyzed on Agilent 2100 Bioanalyser (Agilent
Technologies, CA, USA). The RNA samples had RIN
(RNA integrity number) above 9.
Illumina Human-6 v2 Expression BeadChip (Illumina,
USA) was used for the microarray analysis following the
standard protocol. Total RNA (150 ng) was amplified using
Illumina TotalPrep RNA Amplification Kit (Ambion, USA)
and 15 microgram of amplified RNA was hybridized on
the chip according to the manufacturer’s protocol. All sub-
sequent analyses were done on two biological replicates.
The raw data (TIFF image files) was analyzed with
beadarray package [32] of the BioConductor within the R
environment [33]. All hybridizations passed quality con-
trol. The data was background corrected and normalized
with the probe level quantile method. Before detection of
differential expression, the probes with intensity level
lower than 95-percentile of negative controls of the
BeadChip in all samples were disregarded from the ana-
lysis. Probes with low variation across samples estimated
by the inter-quartile range irrespective of the sample
group were disregarded as well. Differential expression
was detected using the moderated t-test of the limma
package [34] on intensities that were variance-stabilized
by logarithmic transformation. Annotation of the tran-
scripts differentially expressed between simvastatin treated
and the control cultures was done using the manifest
file provided by the manufacturer (HumanWG-6_V2_
0_R2_11223189_A.bgx; Illumina, USA). The transcripts
with false discovery rate (FDR) [35] smaller than 0.05 and
fold change smaller than 0.5 or higher than 2 were
reported and used in the downstream analysis. The re-
sults were deposited to the ArrayExpress database
under accession number E-MTAB-1501. Further, we
performed the gene set enrichment analysis (GSEA) on
KEGG pathways [36] using the Fisher’s exact test and
the approach of Tian [37].
Quantitative real-time PCR
Reverse transcription was performed by QuantiTect
Reverse Transcription Kit (QIAGEN Inc., USA). The
qRT-PCR was performed on LightCycler 2.0 System
using LightCycler 480 DNA SYBR Green I Master kit
(Roche Diagnostics, Germany) and results were analyzed
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ther determined using the R environment [33]. Detailed
description of the analysis and the list of amplicons/
primers of target and housekeeping genes are pro-
vided in ArrayExpress database, accession number E-
MTAB-1501.
Additional file
Additional file 1: Validation of gene expression changes performed
using quantitative real-time polymerase chain reaction (qRT-PCR).
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